Abstract
Background & Objective: Gliomas constitute 81% of malignant brain tumors and exhibit a poor prognosis. Two main events involved in the progression of gliomas are the deregulation of genes via genetic events and the cellular damage resulting from the formation of reactive oxygen species (ROS). In gliomas, epigenetic abnormalities implicated in the deregulation of deoxyribonucleic acid (DNA) methylation, nucleosome rearrangement, and acetylation of histones, have been depicted. The overproduction of ROS has been implicated in the promotion of these modifications.
Conclusion: In this review, we discuss the epigenetic mechanisms and oxidative events that impact gene silencing and its association with the establishment and development of gliomas. Some of these epigenetic marks, or their related proteins, are under investigation for their potential use as biomarkers in clinical trials to propose personalized therapies for patients with glioblastoma.
Keywords: Brain tumors, clinical trials, epigenetics, glioma, malignant, oxidative stress.
Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:Role of Epigenetics and Oxidative Stress in Gliomagenesis
Volume: 16 Issue: 10
Author(s): Yesennia Sanchez-Perez, Ernesto Soto-Reyes, Claudia M. Garcia-Cuellar, Bernardo Cacho-Diaz, Abel Santamaria and Edgar Rangel-Lopez*
Affiliation:
- National Institute of Neurology and Neurosurgery, Laboratory of Excitatory Amino Acids. Av. Insurgentes Sur #3877 Col. La Fama. Delegacion Tlalpan, C.P. 14269 Mexico City,United States
Keywords: Brain tumors, clinical trials, epigenetics, glioma, malignant, oxidative stress.
Abstract: Background & Objective: Gliomas constitute 81% of malignant brain tumors and exhibit a poor prognosis. Two main events involved in the progression of gliomas are the deregulation of genes via genetic events and the cellular damage resulting from the formation of reactive oxygen species (ROS). In gliomas, epigenetic abnormalities implicated in the deregulation of deoxyribonucleic acid (DNA) methylation, nucleosome rearrangement, and acetylation of histones, have been depicted. The overproduction of ROS has been implicated in the promotion of these modifications.
Conclusion: In this review, we discuss the epigenetic mechanisms and oxidative events that impact gene silencing and its association with the establishment and development of gliomas. Some of these epigenetic marks, or their related proteins, are under investigation for their potential use as biomarkers in clinical trials to propose personalized therapies for patients with glioblastoma.
Export Options
About this article
Cite this article as:
Sanchez-Perez Yesennia, Soto-Reyes Ernesto , Garcia-Cuellar M. Claudia, Cacho-Diaz Bernardo , Santamaria Abel and Rangel-Lopez Edgar *, Role of Epigenetics and Oxidative Stress in Gliomagenesis, CNS & Neurological Disorders - Drug Targets 2017; 16 (10) . https://dx.doi.org/10.2174/1871527317666180110124645
DOI https://dx.doi.org/10.2174/1871527317666180110124645 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Anandamide Degradation System as Potential Target for the Treatment of Central Nervous System Related Disorders
Current Medicinal Chemistry - Central Nervous System Agents Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry PNP Anticancer Gene Therapy
Current Topics in Medicinal Chemistry Fluorescence Imaging in Cancerology
Current Molecular Imaging (Discontinued) In Vivo Tumor Secretion Probing Via Ultrafiltration and Tissue Chamber:Implication for Anti-Cancer Drugs Targeting Secretome
Recent Patents on Anti-Cancer Drug Discovery Driving Cellular Plasticity and Survival Through the Signal Transduction Pathways of Metabotropic Glutamate Receptors
Current Neurovascular Research ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy
Current Pharmaceutical Design Gemini Surfactant Based Carriers in Gene and Drug Delivery
Current Medicinal Chemistry Nucleic Acid-Based Aptamers: Applications, Development and Clinical Trials
Current Medicinal Chemistry Glycoconjugates: Roles in Neural Diseases Caused by Exogenous Pathogens
CNS & Neurological Disorders - Drug Targets Production of Alpha Emitters for Targeted Alpha Therapy
Current Radiopharmaceuticals Potential Gene Therapy Strategies for Cancer Stem Cells
Current Gene Therapy Polyisoprenylated Cysteinyl Amide Inhibitors: A Novel Approach to Controlling Cancers with Hyperactive Growth Signaling
Current Medicinal Chemistry Inflammasome as a New Therapeutic Target for Diabetic Complications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy The Role of Tumor-related LncRNA PART1 in Cancer
Current Pharmaceutical Design Novel Homeodomain Transcription Factor Nkx2.2 in the Brain Tumor Development
Current Cancer Drug Targets Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design Recent Advances of MEK Inhibitors and Their Clinical Progress
Current Topics in Medicinal Chemistry